PAROMOMYCIN SULFATE - Generic Drug Details

What are the generic drug sources for paromomycin sulfate and what is the scope of freedom to operate?

Paromomycin sulfate is the generic ingredient in two branded drugs marketed by King Pfizer, Parkedale, Heritage, Sun Pharm Inds Inc, and Parke Davis, and is included in five NDAs. Additional information is available in the individual branded drug profile pages.

There is one drug master file entry for paromomycin sulfate. One supplier is listed for this compound.

Summary for PAROMOMYCIN SULFATE

US Patents:	0
Tradenames:	2
Applicants:	5
NDAs:	5
Drug Master File Entries:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	65
Clinical Trials:	9
Patent Applications:	3,629
What excipients (inactive ingredients) are in PAROMOMYCIN SULFATE?	PAROMOMYCIN SULFATE excipients list
DailyMed Link:	PAROMOMYCIN SULFATE at DailyMed

Recent Clinical Trials for PAROMOMYCIN SULFATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Drugs for Neglected Diseases	Phase 3
The Institute of Endemic Diseases (IEND), University of Khartoum	Phase 3
University of Gondar	Phase 3

See all PAROMOMYCIN SULFATE clinical trials

Pharmacology for PAROMOMYCIN SULFATE

Drug Class

Antiprotozoal

Medical Subject Heading (MeSH) Categories for PAROMOMYCIN SULFATE

Amebicides

Anti-Bacterial Agents

Anatomical Therapeutic Chemical (ATC) Classes for PAROMOMYCIN SULFATE

A07AA	Antibiotics
A07A	INTESTINAL ANTIINFECTIVES
A07	ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
A	Alimentary tract and metabolism

US Patents and Regulatory Information for PAROMOMYCIN SULFATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sun Pharm Inds Inc	PAROMOMYCIN SULFATE	paromomycin sulfate	CAPSULE;ORAL	064171-001	Jun 30, 1997		DISCN	No	No
Parke Davis	HUMATIN	paromomycin sulfate	SYRUP;ORAL	060522-001	Approved Prior to Jan 1, 1982		DISCN	No	No
King Pfizer	HUMATIN	paromomycin sulfate	CAPSULE;ORAL	062310-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Heritage	PAROMOMYCIN SULFATE	paromomycin sulfate	CAPSULE;ORAL	065173-001	Dec 14, 2007		RX	No	Yes
Parkedale	HUMATIN	paromomycin sulfate	CAPSULE;ORAL	060521-001	Approved Prior to Jan 1, 1982		DISCN	No	No

PAROMOMYCIN SULFATE Market Analysis and Financial Projection Experimental

Paromomycin Sulfate Market Dynamics and Financial Trajectory

Introduction to Paromomycin Sulfate

Paromomycin sulfate is an aminoglycoside sulfate salt derived from the treatment of paromomycin with sulfuric acid. It is a potent antimicrobial agent used primarily to treat various parasitic infections, including acute and chronic intestinal amoebiasis, giardiasis, leishmaniasis, and tapeworm infections. Additionally, it is used in conjunction with other medications to manage symptoms of hepatic coma, a complicated liver disease[2].

Market Size and Growth

The global paromomycin sulfate market is projected to experience significant growth over the coming years. As of 2023, the market size was valued at approximately USD 120 million and is expected to reach USD 210 million by 2032. This growth is anticipated at a Compound Annual Growth Rate (CAGR) of around 4.95% during the period of 2024-2032[1][4].

Key Drivers of Market Growth

Several factors are driving the growth of the paromomycin sulfate market:

Rise in Geriatric Population

The increasing geriatric population, which is more prone to chronic intestinal and bowel disorders, is a key driver. Older adults are more likely to suffer from conditions that require treatment with paromomycin sulfate[2].

Adoption of Sedentary Lifestyle

The rise in sedentary lifestyles among the general population leads to an increase in gastrointestinal diseases, thereby boosting the demand for paromomycin sulfate[2].

Awareness and Availability of Medication

Growing awareness among the population about the availability of medications for acute bowel disorders opens up new opportunities for the paromomycin sulfate market[2].

Market Restraints

Despite the positive growth drivers, there are some restraints that could slow down the market growth:

Side Effects

Common side effects such as vomiting and loss of appetite associated with paromomycin sulfate can deter some patients, potentially slowing the market growth rate[2].

Impact of COVID-19

The COVID-19 pandemic has had a significant impact on the pharmaceutical and biotechnology industries, including the paromomycin sulfate market. The high demand for COVID-19 management drugs has presented opportunities for manufacturers, as many countries faced shortages of essential medications. This surge in demand has indirectly benefited the overall pharmaceutical sector, which in turn could influence the paromomycin sulfate market positively[2].

Market Trends

New Product Launches

The market is witnessing new product launches that can enhance treatment options. For example, Pfizer Inc. launched Mucaine Gel Syrup in 2019 to treat hyperacidity, heartburn, and other gastrointestinal issues, which can indirectly support the demand for paromomycin sulfate by addressing related health concerns[2].

Drug Repurposing

Recent studies have explored the potential of paromomycin sulfate in treating COVID-19. Virtual screening of FDA-approved drugs has identified paromomycin as a significant binder against the SAM binding site of NSP16, a protein crucial for SARS-CoV-2 replication. This repurposing could open new avenues for the drug[3].

Market Segmentation

The paromomycin sulfate market can be segmented based on several criteria:

By Type

The market can be segmented into different types of paromomycin sulfate formulations, such as oral and topical preparations.

By Application

The drug is used for various parasitic infections, including amoebiasis, giardiasis, and leishmaniasis.

By Distribution Channel

The market can be segmented based on distribution channels such as hospitals, pharmacies, and online retailers.

By Region

Geographically, the market can be segmented into North America, Europe, Asia-Pacific, and other regions, each with its own growth dynamics and market size[2].

Key Market Players

Several key players are active in the paromomycin sulfate market, including:

• Kaifeng Pharm.
• ERFA Canada
• Changrui Pharm
• Pfizer
• Shanhe Pharm[2].

Financial Projections

The financial trajectory of the paromomycin sulfate market is positive, with a projected market size of USD 210 million by 2032. This growth is driven by increasing demand, new product launches, and the potential for drug repurposing in the context of COVID-19[4].

Porter’s Five Forces Analysis

Porter’s five forces analysis provides insights into the competitive intensity of the market:

• Bargaining Power of Buyers: Moderate to high due to the availability of alternative treatments.
• Bargaining Power of Suppliers: Moderate, as the supply chain is relatively stable.
• Threat of New Entrants: Low to moderate, given the regulatory hurdles and competition from established players.
• Threat of Substitutes: Moderate, as there are other antimicrobial agents available.
• Competitive Rivalry Among Existing Competitors: High, due to the presence of multiple key players[2].

Key Takeaways

• The global paromomycin sulfate market is expected to grow at a CAGR of 4.95% from 2024 to 2032.
• Key drivers include the rise in the geriatric population and sedentary lifestyles.
• Side effects and the availability of alternative treatments are potential restraints.
• The COVID-19 pandemic has indirectly supported the market by increasing demand for pharmaceuticals.
• New product launches and drug repurposing are significant market trends.

Frequently Asked Questions (FAQs)

Q: What is paromomycin sulfate used for? A: Paromomycin sulfate is used to treat various parasitic infections, including acute and chronic intestinal amoebiasis, giardiasis, leishmaniasis, and tapeworm infections. It is also used in conjunction with other medications to manage symptoms of hepatic coma[2].

Q: What is the projected market size of paromomycin sulfate by 2032? A: The global paromomycin sulfate market is projected to reach USD 210 million by 2032[4].

Q: How does the COVID-19 pandemic impact the paromomycin sulfate market? A: The COVID-19 pandemic has indirectly supported the market by increasing the demand for pharmaceuticals and highlighting the potential of paromomycin sulfate in treating COVID-19 through drug repurposing[2][3].

Q: Who are the key players in the paromomycin sulfate market? A: Key players include Kaifeng Pharm., ERFA Canada, Changrui Pharm, Pfizer, and Shanhe Pharm[2].

Q: What are the common side effects of paromomycin sulfate? A: Common side effects include vomiting and loss of appetite[2].

Cited Sources

1. IMARC Group: Paromomycin Sulphate Market Growth, Size, Report 2024-32.
2. Allied Market Research: Paromomycin Sulfate Market Size, Share Forecast- 2030.
3. NCBI: Structural-Based Virtual Screening of FDA-Approved Drugs Repository for NSP16 Inhibitors, Essential for SARS-COV-2 Invasion Into Host Cells.
4. Dataintelo: Paromomycin Sulfate Market Research Report 2032.